Preview

Нервно-мышечные болезни

Расширенный поиск

Иммуноглобулины в неврологической практике: обзор литературы

https://doi.org/10.17650/2222-8721-2019-9-1-32-51

Полный текст:

Аннотация

 Сегодня высокодозная терапия иммуноглобулинами человека получает все большее распространение в лечении болезней нервной системы. Эффективность и безопасность использования иммуноглобулинов доказана в рандомизированных контролируемых исследованиях у пациентов с хронической воспалительной демиелинизирующей полинейропатией, синдромом Гийена–Барре, мультифокальной моторной нейропатией, что отражено в систематических обзорах. Обсуждаются вопросы о дозах, интервалах и продолжительности лечения и необходимости повторных инфузий при этих состояниях. Использование высокодозной терапии иммуноглобулинами является опцией при миастенических кризах и обострениях миастении гравис, синдроме ригидного человека, а также терапией 2-й линии при дерматомиозите и в некоторых случаях при полимиозите. Применение иммуноглобулинов при рассеянном склерозе, миозите с включениями, резистентной эпилепсии остается не до конца обоснованной. В обзоре обсуждается эффективность высокодозной терапии иммуноглобулинами в неврологии на основании информативных исследований, с учетом основных критериев выбора препарата для адекватной внутривенной иммунотерапии.

Об авторах

C. С. Никитин
Медицинский центр «Практическая неврология»; Региональная общественная организация «Общество специалистов по нервно-мышечным болезням»
Россия

117258 Москва, ул. Кржижановского, 17/2, 

117478 Москва, Каширское шоссе, 24/15



Л. М. Борискина
Региональная общественная организация «Общество специалистов по нервно-мышечным болезням»; «Клиника Центральная» ООО «Нормодент-Центр»
Россия

Лидия Михайловна Борискина

117478 Москва, Каширское шоссе, 24/15, 

101000 Москва, ул. Мясницкая, 13/13




Список литературы

1. Cohn E.J., Strong L.E., Hughes W.L. et al. Preparation and properties of serum and plasma proteins; a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc 1946;68:459–75. PMID: 21015743. DOI: 10.1021/ja01207a034.

2. Casadeval A., Dadachova E., Pirofski L.A. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004;2(9):695–703. PMID: 15372080. DOI: 10.1038/nrmicro974.

3. Martin P.R., Scheidegger J.J., Wenger P. et al. Behavior of intramuscular, intravenous and oral gamma globulin. Blut 1959;5(2):104–14. PMID: 13671094.

4. Schultze H.E., Schwick G., Bikhard J. On the antibody nature of properdin. Z Immun Exp Ther 1962;123:307–25. PMID: 13987245.

5. Barandum S., Kistler P., Jeunet F., Isliken H. Intravenous administration of human gamma-globulin. Vox Sang 1962;7:157–74. PMID: 13864762. DOI: 10.1159/000464763.

6. Intravenous immunoglobulin: prevention and treatment of disease. NIH Consens State Sci Statements 2004;21(1):1–23. PMID: 17308551.

7. Imbach P., Barandun S., d’Apuzzo V. et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1(8232):1228–31. PMID: 6112565. DOI: 10.1016/s0140-6736(81)90810-2.).

8. Wahn V., Orange J.S. Clinical use of immunoglobulins. 2nd edition. Bremen: Uni-Med, 2013. P. 251.

9. McLeod J.G., Pollard J.D., Macaskill P. et al. Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol 1999;46:910–3. PMID: 10589544. DOI: 10.1002/1531-8249(199912)46:6<910::aid-ana14>3.0.co;2-2.

10. Баранов А.А., Намазова-Баранова Л.С., Куренков А.Л. и др. Хроническая воспалительная демиелинизирующая полинейропатия. Клинические рекомендации. Электронное издание, 2016. С. 6.

11. Patwa H.S., Chaudhry V., Katzberg H. et al. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorder: report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology 2012;78(13):1009–15. PMID: 22454268. DOI: 10.1212/WNL.0b013e31824de293.

12. Hughes R.A., Donofrio P., Bril V. et al. Intravenous immuneglobulin (10 % caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomized placebocontrolled trial. Lancet Neurol 2008;7:136–44. PMID: 18178525. DOI: 10.1016/S1474-4422(07)70329-0.

13. Mendell J.R., Barohn R.J., Freimer M.L. et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001;56:445–9. PMID: 11222785. DOI: 10.1212/wnl.57.5.938.

14. Hahn A.F., Bolton C.F., Zochodne D., Feasby T.E. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a doubleblind, placebo-controlled, cross-over study. Brain 1996;119:1067–77. PMID: 8813271. DOI: 10.1093/brain/119.4.1067.

15. Vermeulen M., van Doorn P.A., Brand A. et al. Intravenous immunoglobulintreatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebocontrolled study. J Neurol Neurosurg Psychiatry 1993;56:36–9. PMID: 8429321. DOI: 10.1136/jnnp.56.1.36.

16. Hughes R., Bensa S., Willison H. et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50:195–201. PMID: 11506402. DOI: 10.1002/ana.1088.

17. Frenzel W., Wietek S., Svae T.E. et al. Tolerability and safety of octagamR (IVIG): a postauthorization safety analysis of four noninterventional phase IV trials. Int J Clin Pharmacol Ther 2016;54(11):847–55. PMID: 27719744. DOI: 10.1080/10245332.2017.1385892.

18. Wietek S. Octagam® for chronic inflammatory demyelinating polyneuropathy: results from three observational studies Neurodegener Dis Manag 2018;8(4):227–31. PMID: 29517417. DOI: 10.2217/nmt-2018-0006.

19. Киргизов К.И., Скоробогатова Е.В. Внутривенные иммуноглобулины: применение современных физиологичных растворов способно улучшить результаты терапии. Российский журнал детской гематологии и онкологии 2015;2(2):77–83. DOI:10.17650/2311-1267-2015-2-2-77-83.

20. Nevo Y. Childhood chronic inflammatory demyelinating polyneuropathy. Eur J Paediatr Neurol 1998;2(4):169–77. PMID: 10726588. DOI: 10.1016/s1090-3798(98)80016-0.

21. Eftimov F., Winer J.B., Vermeulen M. et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2009;(1):CD001797. PMID: 19160200. DOI: 10.1002/14651858.CD001797.pub2.

22. Rabie M., Nevo Y. Childhood acute and chronic immune-mediated polyradiculoneuropathies. Eur J Paediatr Neurol 2009;13(3):209–18. PMID: 18585069. DOI: 10.1016/j.ejpn.2008.04.009.

23. Lucke M.I., Adrichem M.E., Wieske L. et al. Intravenous immunoglobulins in patients with clinically suspected chronic immune-mediated neuropathy. J Neurol Sci 2019;397:141–5. PMID: 30623818. DOI: 10.1016/j.jns.2018.12.036.

24. Супонева Н.А., Пирадов М.А. Внутривенная иммунотерапия в неврологии. Москва: Горячая линия–Телеком, 2013. С. 312.

25. Raphael J.C., Chastang C., Jais J.P. et al. French Cooperative Group on Plasma Exchange in Guillain–Barre syndrome. Efficiency of plasma exchange in Guillain–Barre syndrome: role of replacement fluids. Ann Neurol 1987;22(6):753–61. PMID: 2893583. DOI: 10.1002/ana.410220612.

26. GBS study group. Plasmapheresis and acute Guillain–Barre syndrome. The Guillain–Barre Syndrome Study Group. Neurology 1985;35:1096–104. PMID: 4022342. DOI:10.1212/WNL.35.8.1096

27. Raphael J.C., Chevret S., Harboun M. et al. Intravenous immune globulins in patients with Guillain–Barre syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry 2001;71(2):235–8. PMID: 11459901. DOI: 10.1136/jnnp.71.2.235.

28. Koningsveld R., Steyerberg E.W., Hughes R.A. et al. A clinical prognostic scoring system for Guillain–Barre syndrome. Lancet Neurol 2007;6(7):589–94. PMID: 17537676. DOI: 10.1016/S1474-4422(07)70130-8.

29. Meche F.G., Schmitz P.I. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain–Barre syndrome. Dutch Guillain–Barre Study Group. N Engl J Med 1992;326(17):1123–9. PMID: 1552913. DOI: 10.1056/NEJM199204233261705.

30. Kleyweg R.P., van der Meche F.G. Treatment related fluctuations in Guillain–Barre syndrome after high-dose immunoglobulins or plasma-exchange. Neurol Neurosurg Psychiatry 1991;54(11):957–60. PMID: 1800666. DOI: 10.1136/jnnp.54.11.957.

31. Visser L.H., Schmitz P.I., Meulstee J. et al. Prognostic factors of Guillain–Barre syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain–Barre Study Group. Neurology 1999;53(3):59–604. PMID: 10449126. DOI: 10.1212/wnl.53.3.598.

32. Bril V., Ilse W.K., Pearce R. et al. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain–Barre syndrome. Neurology 1996;46(1):100–3. PMID: 8559353. DOI: 10.1016/s0887-7963(96)80021-6.

33. PE/Sandoglobulin Guillain–Barre Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain–Barre syndrome. Lancet 1997;349(9047):225–30. PMID: 9014908. DOI: 10.1016/s0140-6736(96)09095-2.

34. Ortiz-Salas P., Velez-Van-Meerbeke A., Galvis-Gomez C.A., Rodriguez Q.J. Human immunoglobulin versus plasmapheresis in Guillain–Barre syndrome and myasthenia gravis: a meta-analysis. J Clin Neuromuscul Dis 2016;18(1):1–11. DOI: 10.1097/CND.0000000000000119.

35. Haupt W.F., Birkmann C., van der Ven C., Pawlik G. Apheresis and selective adsorption plus immunoglobulin treatment in Guillain–Barre syndrome. Ther Apher 2000;4(3):198–200. PMID: 10910019. DOI: 10.1046/j.1526-0968.2000.00182.x.

36. Koningsveld R., Schmitz P.I., Meche F.G. et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain–Barre syndrome: randomised trial. Lancet 2004;363(9404):192–6. PMID: 14738791. DOI: 10.1016/s0140-6736(03)15324-x.

37. Kuitwaard K., de Gelder J., Tio-Gillen A.P. et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain–Barre syndrome. Ann Neurol 2009;66(5):597–603. PMID: 19938102. DOI: 10.1002/ana.21737.

38. Godoy D.A., Rabinstein A. Is a second cycle of immunoglobulin justified in axonal forms of Guillain–Barre syndrome? Arq Neuropsiquiatr 2015;73(10):848–51. PMID: 26465402. DOI: 10.1590/0004-282X20150136.

39. Walgaard C., Jacobs B.C., Lingsma H.F. et al. Second IVIg course in Guillain– Barre syndrome patients with poor prognosis (SID-GBS trial): Protocol for a double-blind randomized, placebocontrolled clinical trial. J Peripher Nerv Syst 2018;23(4):210–5. PMID: 30151941. DOI: 10.1111/jns.122860.

40. Hughes R.A., Swan A.V., van Doorn P.A. Intravenous immunoglobulin for Guillain–Barre syndrome. Cochrane Database Syst Rev 2010;(6):CD002063. PMID: 20556755. DOI: 10.1002/14651858.CD002063.pub4.

41. Kuwabara S., Mori M., Ogawara K. et al. Intravenous immunoglobulin therapy for Guillain–Barre syndrome with IgG anti-GM1 antibody. Muscle Nerve 2001;24(1):54–8. PMID: 11150966. DOI: 10.1002/1097-4598(200101)24:1<54::aid-mus6>3.0.co;2-9.

42. Romano J.G., Rotta F.T., Potter P. et al. Relapses in the Guillain–Barre syndrome after treatment with intravenous immune globulin or plasma exchange. Muscle Nerve 1998;21(10):1327–30. PMID: 9736064. DOI: 10.1002/(sici)1097-4598(199810)21:10<1327::aidmus14>3.3.co;2-9.

43. Odaka M., Tatsumoto M., Hoshiyama E. et al. Side effects of combined therapy of methylprednisolone and intravenous immunoglobulin in Guillain–Barre syndrome. Eur Neurol 2005;53(4):194–6. PMID: 15970631. DOI: 10.1159/000086477.

44. Ceccarelli M., Pifferi M., Simoni F. et al. Initial experiences in the use of intravenous immunoglobulins in Guillain–Barre–Strohl syndrome. Pediatr Med Chir 1987;9(6):719–21. PMID: 3444744.

45. Rapin F., Astruc J., Echenne B., Rodière M. Pediatric use of intravenous immunoglobulins in immunomodulation. Apropos of 34 cases. Current data. Ann Pediatr (Paris) 1988;35(7):481–8. PMID: 3178111.

46. Nicolaides P., Appleton R.E. Immunoglobulin therapy in Guillain– Barre syndrome in children. Dev Med Child Neurol 1995;37(12):1110–4. PMID: 8566469. DOI: 10.1111/j.1469-8749.1995.tb11972.x.

47. Vallee L., Dulac O., Nuyts J.P. et al. Intravenous immune globulin is also an efficient therapy of acute Guillain– Barre syndrome in affected children. Neuropediatrics 1993;24(4):235–6. PMID: 8232785. DOI: 10.1055/s-2008-1071548.

48. Yata J., Nihei K., Ohya T. et al. High-dose immunoglobulin therapy for Guillain– Barre syndrome in Japanese children. Pediatr Int 2003;45(5):543–9. PMID: 14521529. DOI: 10.1046/j.1442-200x.2003.01768.x.

49. Korinthenberg R., Schessl J., Kirschner J., Mönting J.S. Intravenously administered immunoglobulin in the treatment of childhood Guillain–Barre syndrome: a randomized trial. Pediatrics 2005;116(1):8–14. PMID: 15995024. DOI: 10.1542/peds.2004-1324.

50. Gürses N., Uysal S., Cetinkaya F. et al. Intravenous immunoglobulin treatment in children with Guillain–Barre syndrome. Scand J Infect Dis 1995;27(3):241–3. PMID: 8539548. DOI: 10.3109/00365549509019016.

51. Vajsar J., Sloane A., Wood E., Murphy E.G. Plasmapheresis vs intravenous immunoglobulin treatment in childhood Guillain–Barre syndrome. Arch Pediatr Adolesc Med 1994;148(11):1210–2. PMID: 7921126. DOI: 10.1001/archpedi.1994.02170110096019.

52. Graf W.D., Katz J.S., Eder D.N. et al. Outcome in severe pediatric Guillain– Barre syndrome after immunotherapy or supportive care. Neurology 1999;52(7):1494–7. PMID: 10227643. DOI: 10.1212/wnl.52.7.1494.

53. Korinthenberg R., Mönting J.S. Natural history and treatment effects in Guillain– Barre syndrome: a multicentre study. Arch Dis Child 1996;74(4):281–7. PMID: 8669925. DOI: 10.1136/adc.74.4.281.

54. Reisin R.C., Pociecha J., Rodriguez E. et al. Severe Guillain–Barre syndrome in childhood treated with human immune globulin. Pediatr Neurol 1996;14(4):308–12. PMID: 8805174. DOI: 10.1016/0887-8994(96)00050-1.

55. Kanra G., Ozon A., Vajsar J. et al. Intravenous immunoglobulin treatment in children with Guillain–Barre syndrome. Eur J Paediatr Neurol 1997;1(1):7–12. PMID: 10728186. DOI: 10.1016/s1090-3798(97)80004-9.

56. McGhee B., Jarjour I.T. Single-dose intravenous immune globulin for treatment of Guillain–Barre syndrome. Am J Hosp Pharm 1994;51(1):97–9. PMID: 8135270. DOI: 10.1093/ajhp/51.1.97.

57. Shahar E., Shorer Z., Roifman C.M. et al. Immune globulins are effective in severe pediatric Guillain–Barre syndrome. Pediatr Neurol 1997;16(1):32–6. PMID: 9044398. DOI: 10.1016/s0887-8994(96)00253-6.

58. Pestronk A. Multifocal motor neuropathy: diagnosis and treatment. Neurology 1998;51(5):S22–4. PMID: 9851726. DOI: 10.1212/wnl.51.6_suppl_5.s22.

59. Bouche P., Moulonguet A., YounesChennoufi A.B. et al. Multifocal motor neuropathy with conduction block: a study of 24 patients. J Neurol Neurosurg Psychiatry 1995;59(1):38–44. PMID: 7608707. DOI: 10.1136/jnnp.59.1.38.

60. Schuchardt V., Hotz M., Hund E. et al. Experiences with high dosage immunoglobulin G in neuromuscular diseases. Nervenarzt 1993;64(2):98–103. PMID: 8450901.

61. Leger J.M., Chassande B., Musset L. et al. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a doubleblind, placebo-controlled study. Brain 2001;124:145–53. PMID: 11133794. DOI: 10.1093/brain/124.1.145.

62. Federico P. Zochodne D.W., Hahn A.F. et al. Multifocal motor neuropathy improved by IVIg: randomized, doubleblind, placebo-controlled study. Neurology 2000;55:1256–62. PMID: 11087764. DOI: 10.1212/wnl.55.9.1256.

63. Azulay J.P., Blin O., Pouget J. et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology 1994;44:429–32. PMID: 8145910. DOI: 10.1212/wnl.44.3_part_1.429.

64. Van den Berg L.H., Kerkhoff H., Oey P.L. et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo-controlled study. J Neurol Neurosurg Psychiatry 1995;59(3):248–52. PMID: 7673950. DOI: 10.1136/jnnp.59.3.248.

65. Koski C., Beydoun S., Schiff R. et al. Efficacy, safety, and tolerability of intravenous gammaglobulin (IGIV, 10%) in a Phase 3, randomized, placebocontrolled, cross-over trial for the treatment of multifocal motor neuropathy (MMN). Neurology 2012;78(1):PL02.002. DOI: 10.1212/WNL.78.1_MeetingAbstracts.PL02.002.

66. Jinka M., Chaudhry V. Treatment of multifocal motor neuropathy. Curr Treat Options Neurol 2014;16(2):269. PMID: 24395647. DOI: 10.1007/s11940-013-0269-y.

67. Toyka K.V., Hartung H.P. Chronic inflammatory polyneuritis and neuropathies. Curr Opin Neurol 1996;9(3):240–50. PMID: 8839619. DOI: 10.1097/00019052-199606000-00016.

68. Van den Berg L.H., Franssen H., Wokke J.H. The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy. Brain 1998;121(Pt 3): 421–8. PMID: 9549518. DOI: 10.1093/brain/121.3.421.

69. Van den Berg-Vos R.M., Franssen H., Wokke J.H., Van den Berg L.H. Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain 2002;125(Pt8):1875–86. PMID: 12135977. DOI: 10.1093/brain/awf193.

70. Никитин С.С., Наумова Е.С., Дружинин Д.С. Оценка динамики площади поперечного сечения периферических нервов при мультифокальной моторной нейропатии по данным ультразвукового исследования на фоне внутривенной терапии иммуноглобулинами: описание клинического случая. Нервно-мышечные болезни 2016;6(4):46–51. DOI: 10.17650/2222-8721-2016-6-4-46-51.

71. Vucic S., Black K.R., Chong P.S., Cros D. Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg. Neurology 2004;63(7):1264–9. PMID: 15477549. DOI: 10.1212/01.wnl.0000140497.85952.fa.

72. Baumann A., Hess C.W., Sturzenegger M. IVIg dose increase in multifocal motor neuropathy: a prospective six month follow-up. J Neurol 2009;256(4):608–14. PMID: 19367358. DOI: 10.1007/s00415-009-0130-0.

73. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 2006;11(1):9–19. PMID: 16519778. DOI: 10.1111/j.1085-9489.2006.00059.x.

74. Comi G., Roveri L., Swan A. et al. A randomized controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol 2002;249:1370–7. PMID: 12382151. DOI: 10.1007/s00415-002-0808-z.

75. Dalakas M.C., Quarles R.H., Farrer R.G. et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 1996;40(5):792–5. PMID: 8957021. DOI: 10.1002/ana.410400516.

76. Mariette X., Chastang C., Clavelou P. et al. A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM-associated Polyneuropathy Study Group. J Neurol Neurosurg Psychiatry 1997;63(1):28–34. PMID: 9221964. DOI: 10.1136/jnnp.63.1.28.

77. Fateh-Moghadam A., Besinger U., Wick M. High-dose immunoglobulin therapy in autoimmune diseases. Immun Infekt 1984;12(2):129–33. PMID: 6085502.

78. Ippoliti G., Cosi V., Piccolo G. et al. High dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984;6:809. PMID: 6148545. DOI: 10.1016/s0140-6736(84)90729-3.

79. Arsura E.L., Bick A., Brunner N.G. et al. High-dose intravenous immunoglobulin in the management of myasthenia gravis. Arch Intern Med 1986;146(7):1365–8. PMID: 3718134. DOI: 10.1001/archinte.1986.00360190143020.

80. Balzereit F., Fateh-Moghadam A., Besinger K. et al. Myasthenia gravis. Humorale diagnostic und therapie einer autoimmukrankheit. MMW 1986;128:654–7.

81. Gajdos P., Outin H., Morel E. et al. High dose intravenous gammaglobulin for myasthenia gravis: an alternative to plasma exchange? Ann N Y Acad Sci 1987;505:842–4. DOI: 10.1111/j.1749-6632.1987.tb51387.x.

82. Cosi V., Lombardi M., Piccolo G., Erbetta A. Treatment of myasthenia gravis with highdose intravenous immunoglobulin. Acta Neurol Scand 1991;84(2):81–4. PMID: 1950455. DOI: 10.1111/j.1600-0404.1991.tb04912.x.

83. Hilkevich O., Drory V.E., Chapman J., Korczyn A.D. The use of intravenous immunoglobulin as maintenance therapy in myasthenia gravis. Clin Neuropharmacol 2001;24(3):173–6. PMID 11391130. DOI: 10.1097/00002826-200105000-00010.

84. Uchiyama M., Ichikawa Y., Takaya M. et al. High dose gamma globulin therapy of generalized myasthenia gravis. Ann NY Acad Sci 1987;505:868–70. DOI: 10.1111/j.1749-6632.1987.tb51396.x.

85. Huang C.S., Hsu H.S., Kao K.P. et al. Intravenous immunoglobulin in the preparation of thymectomy for myasthenia gravis. Acta Neurol Scand 2003;108(2):136–8. PMID: 12859292. DOI: 10.1034/j.1600-0404.2003.00131.x.

86. Ronager J., Ravnborg M., Hermansen I., Vorstrup S. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs 2001;25(12):967–73. PMID: 11843764. DOI: 10.1046/j.1525-1594.2001.06717.x.

87. Liu J.F., Wang W.X., Xue J. et al. Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis. Ther Apher Dial 2010;14(2):153–60. PMID: 20438536. DOI: 10.1111/j.1744-9987.2009.00751.x.

88. Zinman L., Ng E., Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 2007;68(11):837–41. PMID: 17353471. DOI: 10.1212/01.wnl.0000256698.69121.45.

89. Sakano T., Hamasaki T., Kinoshita Y. et al. Treatment for refractory myasthenia gravis. Arch Dis Child 1989;64(8):1191–3. PMID: 2782938. DOI: 10.1136/adc.64.8.1191.

90. Herrmann D.N., Carney P.R., Wald J.J. Juvenile myasthenia gravis: treatment with immune globulin and thymectomy. Pediatr Neurol 1998;18(1):63–6. PMID: 9492094. DOI: 10.1016/s0887-8994(97)00136-7.

91. Selcen D., Dabrowski E.R., Michon A.M., Nigro M.A. High-dose intravenous immunoglobulin therapy in juvenile myasthenia gravis. Pediatr Neurol. 2000;22(1):40–3. PMID: 10669204. DOI: 10.1016/s0887-8994(99)00112-5.

92. Bassan H., Muhlbaur B., Tomer A., Spirer Z. High-dose intravenous immunoglobulin in transient neonatal myasthenia gravis. Pediatr Neurol. 1998;18(2):181–3. PMID: 9535308. DOI: 10.1016/s0887-8994(97)00174-4.

93. Tagher R.J., Baumann R., Desai N. Failure of intravenously administered immunoglobulin in the treatment of neonatal myasthenia gravis. J Pediatr 1999;134(2):233–5. PMID: 9931536. DOI: 10.1016/s0022-3476(99)70422-1.

94. Stricker R.B., Kwiatkowska B.J., Habis J.A. et al. Myasthenic Crisis. Response to Plasmapheresis Following Failure of Intravenous γ-Globulin. Arch Neurol 1993;50(8):837–40. PMID: 8352670. DOI:10.1001/archneur.1993.00540080046012.

95. Achiron A., Barak Y., Miron S., Sarova‐ Pinhas I. Immunoglobulin treatment in refractory myasthenia gravis. Muscle Nerve 2000;4(23);551–5. PMID: 10716766. DOI: 10.1002/(sici)1097-4598(200004)23:4<551::aidmus14>3.3.co;2-f.

96. Gajdos P., Tranchant C., Clair B. et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized doubleblind clinical trial. Arch Neurol 2005;62(11):1689–93. PMID: 16286541. DOI: 10.1001/archneur.62.11.1689.

97. Gajdos P., Chevret S., Clair B. et al. Plasma exchange and intravenous immunoglobulin in autoimmune myasthenia gravis. Ann N Y Acad Sci 1998;841:720–6. PMID: 9668320. DOI: 10.1111/j.1749-6632.1998.tb11008.x

98. Qureshi A.I., Choudhry M.A., Akbar M.S. et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 1999;52(3):629–32. PMID: 10025801. DOI: 10.1212/wnl.52.3.629.

99. Barth D., Nabavi N.M., Ng E. et al. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 2011;76(23):2017–23. PMID: 21562253. DOI: 10.1212/WNL.0b013e31821e5505.

100. Gajdos P., Chevret S., Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2008;(1):CD002277. PMID: 18254004. DOI: 10.1002/14651858.CD002277.pub3.

101. Beecher G., Anderson D., Siddiqi Z.A. Subcutaneous immunoglobulin in myasthenia gravis exacerbation: A prospective, open-label trial. Neurology 2017;89(11):1135–41. PMID: 28814461. DOI: 10.1212/WNL.0000000000004365.

102. Dalakas M.C. Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol 2019;15(2):113–24. PMID: 30573759. DOI: 10.1038/s41582-018-0110-z.

103. Bain P.G., Motomura M., Newsom-Davis J. et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert–Eaton myasthenic syndrome. Neurology 1996;47(3):678–83. PMID: 8797464. DOI: 10.1212/wnl.47.3.678.

104. Muchnik S., Losavio A.S., Vidal A. et al. Long-term follow-up of Lambert–Eaton syndrome treated with intravenous immunoglobulin. Muscle Nerve 1997;20(6):674–8. PMID: 9149073. DOI: 10.1002/(sici)1097-4598(199706)20:6<674::aid-mus3>3.0.co;2-5.

105. Rich M.M., Teener J.W., Bird S.J. Treatment of Lambert-Eaton syndrome with intravenous immunoglobulin. Muscle Nerve 1997;20(5):614–5. PMID: 9140371. DOI: 10.1002/(sici)1097-4598(199705)20:5<614::aidmus13>3.0.co;2-w.

106. Takano H., Tanaka M., Koike R. et al. Effect of intravenous immunoglobulin in Lambert–Eaton myasthenic syndrome with small-cell lung cancer: correlation with the titer of anti-voltage-gated calcium channel antibody. Muscle Nerve 1994;17(9):1073–5. PMID: 8065398. DOI: 10.1002/mus.880170919.

107. Okada A., Koike H., Nakamura T. et al. Efficacy of intravenous immunoglobulin for treatment of Lambert–Eaton myasthenic syndrome without antipresynaptic P/Q-type voltage-gated calcium channel antibodies: a case report. Neuromuscul Disord 2015;25(1):70–2. PMID: 25444432. DOI: 10.1016/j.nmd.2014.08.006.

108. Dalakas M.C., Illa I., Dambrosia J.M. et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329(27):1993–2000. PMID: 8247075. DOI: 10.1056/NEJM199312303292704.

109. Cherin P., Herson S., Wechsler B. et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 1991;91(2):162–8. PMID: 1714235. DOI: 10.1016/0002-9343(91)90009-m.

110. Cherin P., Herson S. Indications for intravenous gammaglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry 1994;57:50–4. PMID: 7964854. DOI: 10.1136/jnnp.57.suppl.50.

111. Cherin P., Piette J.C., Wechsler B. et al. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. J Rheumatol 1994;21(6):1092–7. PMID: 7932419.

112. Cherin P., Pelletier S., Teixeira A. et al. Results and long-term follow up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 2002;46(2):467–74. PMID: 11840450. DOI: 10.1002/art.10053.

113. Foreman C., Russo P., Davies N. et al. Use of intravenous immunoglobulin therapy for myositis: an audit in South Australian patients. Intern Med J 2017;47(1):112–5. PMID: 28076913. DOI: 10.1111/imj.13308.

114. Vermaak E., Tansley S.L., McHugh N.J. The evidence for immunotherapy in dermatomyositis and polymyositis: a systematic review. Clin Rheumatol 2015;34(12):2089–95. PMID: 26299472. DOI: 10.1007/s10067-015-3059-y.

115. Soueidan S.A., Dalakas M.C. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 1993;43(5):876–9. PMID: 8492940. DOI: 10.1212/wnl.43.5.876.

116. Dalakas M.C., Sonies B., Dambrosia J. et al. Treatment of inclusion-body myositis with IVIg: a double-blind, placebocontrolled study. Neurology 1997;48(3):712–6. PMID: 9065553. DOI: 10.1212/wnl.48.3.712.

117. Dalakas M.C., Koffman B., Fujii M. et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001;56(3):323–7. PMID: 11171896. DOI: 10.1212/wnl.56.3.323.

118. Walter M.C., Lochmüller H., Toepfer M. et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 2000;247(1):22–8. PMID: 10701893. DOI: 10.1007/s004150050005.

119. Poehlau D., Federlein J., Postert T. et al. Intravenous immunoglobulin (IVIG) treatment for patients with primary or secondary progressive multiple sclerosis - outline of a double-blind randomized, placebo-controlled trial. Mult Scler 1997;2(3):149–52. PMID: 9291171. DOI: 10.1177/135245859700300217.

120. Tselis A., Perumal J., Caon C. et al. Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin. Eur J Neurol 2008;15(11):1163–7. PMID: 18727675. DOI: 10.1111/j.1468-1331.2008.02258.x.

121. Elovaara I., Kuusisto H., Wu X. et al. Intravenous immunoglobulins are a therapeutic option in the treatment of multiple sclerosis relapse. Clin Neuropharmacol 2011;34(2):84–9. PMID: 21301327. DOI: 10.1097/WNF.0b013e31820a17f3.

122. Sorensen P.S., Haas J., Sellebjerg F. et al. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology 2004;63(11):2028–33. PMID: 15596745. DOI: 10.1212/01.wnl.0000145798.61383.39.

123. Visser L.H., Beekman R., Tijssen C.C. et al. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS. Mult Scler 2004;10(1):89–91. PMID: 14760960. DOI: 10.1191/1352458504ms978sr.

124. Pöhlau D., Przuntek H., Sailer M. et al. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Mult Scler 2007;13(9):1107–17. PMID: 17623736. DOI: 10.1177/1352458507078400.

125. Noseworthy J.H., O’Brien P.C., Weinshenker B.G. et al. IV immunoglobulin does not reverse established weakness in MS. Neurology 2000;55(8):1135–43. PMID: 11071491. DOI: 10.1212/wnl.55.8.1135.

126. Noseworthy J.H., O’Brien P.C., Petterson T.M. et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001;56:1514–22. PMID: 11402108. DOI: 10.1016/s0002-9394(01)01226-0.

127. Stangel M., Boegner F., Klatt C.H. et al. Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000;68(1):89–92. PMID: 10601410. DOI: 10.1136/jnnp.68.1.89.

128. Pechadre J.C., Sauvezie B., Osier C., Gibert J. The treatment of epileptic encephalopathies with gamma globulin in children (author’s transl). Rev Electroencephalogr Neurophysiol Clin 1977;7(4):443–7. PMID: 77033.

129. Duse M., Tiberti S., Plebani A. et al. IgG2 deficiency and intractable epilepsy of childhood. Monogr Allergy 1986;20:128–34. PMID: 3773903.

130. Engelen B.G., Renier W.O., Weemaes C.M. et al. Immunoglobulin treatment in epilepsy, a review of the literature. Epilepsy Res 1994;19(3):181–90. PMID: 7698094. DOI: 10.1016/0920-1211(94)90061-2.

131. Villani F., Avanzini G. The use of immunoglobulins in the treatment of human epilepsy. Neurol Sci 2002;23(1):S33–7. PMID: 12032585. DOI: 10.1007/s100720200013.

132. Rijckevorsel-Harmant K., Delire M., Schmitz-Moorman W., Wieser H.G. Treatment of refractory epilepsy with intravenous immunoglobulins. Results of the first double-blind/dose finding clinical study. Int J Clin Lab Res 1994;24(3):162–6. PMID: 7819596. DOI: 10.1007/bf02592447.

133. Aarli J.A. Immunological aspects of epilepsy. Brain Dev 1993;15(1):41–9. PMID: 8338210. DOI: 10.1016/0387-7604(93)90005-s.

134. Barontini F., Maurri S., Amantini A. “Epilepsia partialis continua” due to multifocal encephalitis: favourable outcome after immunoglobulin treatment. Ital J Neurol Sci 1994;15(3):157–61. PMID: 8056563. DOI: 10.1007/bf02339208.

135. Sandstedt P., Kostulas V., Larsson L.E. Intravenous gammaglobulin for postencephalitic epilepsy. Lancet 1984;8412(324):1154–5. PMID: 6209514. DOI: 10.1016/S0140-6736(84)91585-X.

136. Fayad M.N., Choueiri R., Mikati M. Landau–Kleffner syndrome: consistent response to repeated intravenous gammaglobulin doses: a case report. Epilepsia 1997;38(4):489–94. PMID: 9118856. DOI: 10.1111/j.1528-1157.1997.tb01740.x.

137. Lagae L.G., Silberstein J., Gillis P.L., Casaer P.J. Successful use of intravenous immunoglobulins in Landau–Kleffner syndrome. Pediatr Neurol 1998;18(2):165–8. PMID: 9535304. DOI: 10.1016/s0887-8994(97)00157-4.

138. Mikati M.A., Saab R. Successful use of intravenous immunoglobulin as initial monotherapy in Landau–Kleffner syndrome. Epilepsia 2000;41(7):880–6. PMID: 10897161. DOI: 10.1111/j.1528-1157.2000.tb00257.x.

139. Mikati M.A., Saab R., Fayad M.N., Choueiri R.N. Efficacy of intravenous immunoglobulin in Landau–Kleffner syndrome. Pediatr Neurol 2002;26(4):298–300. PMID: 11992758. DOI: 10.1016/s0887-8994(01)00402-7.

140. Mikati M.A., Kurdi R., El-Khoury Z. et al. Intravenous immunoglobulin therapy in intractable childhood epilepsy: openlabel study and review of the literature. Epilepsy Behav 2010;17(1):90–4. PMID: 20004620. DOI: 10.1016/j.yebeh.2009.10.020.

141. Karlson E.W., Sudarsky L., Ruderman E. et al. Treatment of stiff-man syndrome with intravenous immune globulin. Arthritis Rheum 1994;37(6):915–8. PMID: 8003064, DOI: 10.1002/art.1780370621.

142. Barker R.A., Marsden C.D. Successful treatment of stiff man syndrome with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 1997;62(4):426–7. PMID: 9120475. DOI: 10.1136/jnnp.62.4.426.

143. Dalakas M.C., Fujii M., Li M. et al. Highdose intravenous immune globulin for stiff-person syndrome. N Engl J Med 2001;345(26):1870–6. PMID: 11756577. DOI: 10.1056/NEJMoa01167.

144. Cherin P., Cabane J. Relevant criteria for selecting an intravenous immunoglobulin preparation for clinical use. BioDrugs 2010;24(4):211–23. PMID: 20623988. DOI: 10.2165/11537660-000000000-00000.

145. Debes A., Bauer M., Kremer S. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study. Pharmacoepidemiol Drug Saf 2007;16(9):1038–47. PMID: 17636556. DOI: 10.1002/pds.1449.

146. Wiles C.M., Brown P., Chapel H. et al. Intravenous immunoglobulin in neurological disease: a specialist review. J Neurol Neurosurg Psychiatry 2002;72(4):440–8. PMID: 11909900.

147. Maródi L. Regulation of antiinflammatory activity of intravenous immunoglobulin via inhibitory Fcγ- receptors. Pediatr Res 2001;50:551. DOI: 10.1203/00006450-200111000-00001.

148. Kazatchkine M.D., Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345(10):747–55. PMID: 11547745. DOI: 10.1056/nejmra993360.

149. Shah S. Pharmacy considerations for the use of IGIV therapy. Am J Health Syst Pharm 2005;62(16):S5–11. PMID: 16100386. DOI: 10.2146/ajhp050282.

150. Lemm G. Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy. Neurology 2002;59(12):S28–32. PMID: 12499468. DOI: 10.1212/wnl.59.12_suppl_6.s28.

151. Cherin P., Cabane J. Relevant criteria for selecting an intravenous immunoglobulin preparation for clinical use. BioDrugs. 2010;24(4):211–23. PMID: 20623988. DOI: 10.2165/11537660-000000000-00000.

152. Кондратенко И.В., Бологов А.А. Внутривенные иммуноглобулины, от создания до наших дней. Педиатрия 2018;97(6):135–43. DOI: 10.24110/0031-403X-2018-97-6-124-132.

153. Dantal J. Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk. Am J Nephrol 2013;38:275–84. PMID: 24051350. DOI: 10.1159/000354893.

154. Debes A., Bauer M., Kremer S. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study. Pharmacoepidemiol Drug Saf 2007;16(9):1038–47. PMID: 17636556. DOI: 10.1002/pds.1449.


Для цитирования:


Никитин C.С., Борискина Л.М. Иммуноглобулины в неврологической практике: обзор литературы. Нервно-мышечные болезни. 2019;9(1):32-51. https://doi.org/10.17650/2222-8721-2019-9-1-32-51

For citation:


Nikitin S.S., Boriskina L.M. Immunoglobulins in neurological practice: a review of the literature. Neuromuscular Diseases. 2019;9(1):32-51. (In Russ.) https://doi.org/10.17650/2222-8721-2019-9-1-32-51

Просмотров: 152


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2222-8721 (Print)
ISSN 2413-0443 (Online)